关于“激光治疗”的报告
-
-
艾媒咨询|2021-2022年中国医美器械产业运行及投资决策分析报告
本报告研究涉及企业/品牌/案例：科医人，复星医药，奇致激光，半岛医疗
伴随着医美市场规模的持续扩大，中国医美器械行业发展前景可期。数据显示，预计2021年中国医美器械市场规模将超过500亿元，同比增长27.8%。从细分赛道来看，近年来，微创和无创已逐渐成为医疗美容的趋势，这就推动了以激光、超声波等能量源为代表的光电类医美器械的发展。从市场格局来看，中国正规医美机构设备的市场份额80%是进口品牌，且中高端市场被飞顿、塞诺龙等海外龙头企业占领。为了改变这一局面，国家及地方先后出台政策鼓励本土医美器械品牌的发展，同时，国有品牌也通过加大自主研发投入和投资并购来扩大市场份额，未来随着下游扩张、需求渗透、技术更新等因素有望加速进口替代。
With the continuous expansion of the medical beauty market, the development prospect of the medical beauty equipment industry in China is promising. According to the data, it is estimated that in 2021, the market size of medical devices in China will exceed 50 billion yuan, with a year-on-year growth of 27.8%. From the perspective of subdivision, in recent years, minimally invasive and non-invasive have gradually become the trend of medical beauty, which promotes the development of photoelectric medical beauty devices represented by laser, ultrasonic and other energy sources. From the perspective of market structure, 80% of the market share of China's regular medical and beauty institutions' equipment is imported brands, and the medium and high-end market is occupied by overseas leading enterprises such as feton and sinolon. In order to change this situation, the state and local governments have successively issued policies to encourage the development of local medical and beauty equipment brands. At the same time, the state-owned brands also expand their market share by increasing independent R & D investment and investment in M & A. in the future, with the downstream expansion, demand penetration, technology update and other factors, it is expected to accelerate the import substitution. -
艾媒咨询｜2021年中国美容美发行业投资机遇及总体趋势研究报告
数据显示，2015-2021年中国美容美发行业市场规模复合增长率为4.0%，2021年市场规模为3863亿元。随着国民生活水平的提高以及对生活品质的不断追求，美容美发业的消费需求旺盛，上下游产业和新兴业态快速发展，预估2022年中国美容美发行业市场规模将突破4000亿元。且值得注意的是，在备案完善、监督加强及违法经营成本提升的背景下，中国化妆品行业将加速整顿，有效保障产品安全及其功效的稳定性，具有较强研发实力的品牌有望占据更大的市场份额。随着新消费群体逐渐成为购买主力，不能快速响应市场的品牌面临淘汰，大规模企业兼并即将到来。
According to the data, the compound growth rate of the market scale of China's beauty salon industry from 2015 to 2021 was 4.0%, and the market scale in 2021 was 386.3 billion yuan. With the improvement of national living standards and the continuous pursuit of quality of life, the consumption demand of beauty salon industry is strong, and the upstream and downstream industries and emerging business forms are developing rapidly. It is estimated that the market scale of China's beauty salon industry will exceed 400 billion yuan in 2022. It is worth noting that under the background of perfect filing, strengthened supervision and increased illegal operating costs, China's cosmetics industry will accelerate the rectification and effectively ensure the stability of product safety and efficacy. Brands with strong R & D strength are expected to occupy a larger market share. As new consumer groups gradually become the main force of purchase, brands that cannot respond quickly to the market are facing elimination, and large-scale enterprise mergers are coming. -
艾媒咨询|2021年中国轻医美行业研究及产业链分析报告
本报告研究涉及企业/品牌/案例：爱美客，华熙生物，奇致激光，华韩整形，新氧，兰州生物
数据显示，2020年中国轻医美用户市场规模达到1520万人，预计到2021年将增至1813万人。在消费意识觉醒和消费需求驱动下，机构、医生在供给端强势助推轻医美行业更快速发展，预计2021年中国轻医美市场将达到798亿元，同比增长46.4%。在行业快速增长的同时，轻医美产业链各环节企业由于集中度不同导致利润分配不均，具体来看，上游原料耗材企业由于高技术壁垒，市场集中度较高，毛利率高于中下游企业，如知名玻尿酸、肉毒素产品制造企业爱美客、华熙生物等，而中下游由于竞争分散，单体获利参差不齐，更容易产生乱象。但总体来说，在行业监管加强、机构自律、平台监督等多方力量共同作用下，轻医美行业将会向线上化、品牌化、规范化发展。
According to the data, the market size of China's light medical beauty users will reach 15.2 million in 2020, and it is expected to increase to 18.13 million by 2021. Driven by the awakening of consumer awareness and consumer demand, institutions and doctors strongly boost the rapid development of light medical beauty industry in the supply side. It is estimated that China's light medical beauty market will reach 79.8 billion yuan in 2021, with a year-on-year growth of 46.4%. With the rapid growth of the industry, the profit distribution of enterprises in each link of the light medical beauty industry chain is uneven due to different concentration. Specifically, due to high technical barriers, the upstream raw materials and consumables enterprises have higher market concentration and higher gross profit rate than the middle and downstream enterprises, such as the well-known hyaluronic acid, botulinum toxin product manufacturing enterprises aimekke, Huaxi biology, etc., while the middle and downstream enterprises have higher gross profit rate due to scattered competition, Individual profit is uneven, more likely to produce chaos. But on the whole, under the joint action of industry supervision, institutional self-discipline, platform supervision and other forces, the light medical beauty industry will develop to online, brand and standardization. -
-
艾媒咨询|2020年中国细胞生物产业和商业应用分析报告
本报告研究涉及企业/品牌/案例：华夏源、复星医药。
中国细胞生物产业类型呈现多样化趋势，细胞生物临床研究不断深化，伴随生态合作的拓展将进一步加速细胞生物产业生态圈的形成，生态圈的完善将在很大限度上推动产业快速发展。数据显示，中国细胞治疗企业融资金额不断增加，从2014年的0.2亿元增长至2019年的28.9亿元。其中，2018年中国细胞治疗企业融资额同比增长706.8%，呈现迅猛发展态势。未来中国细胞生物产业的发展将充满机遇，同时也有挑战并存。后续产业的发展，将在5G、人工智能等新技术应用下加速升级。面临多端变化的市场格局，企业也应积极开展生态合作以及更为密切关注市场需求动向，将疗法和新一代医疗创新技术深度融合，实现市场产品多元化与差异化，并推出独特性的精准治疗，从而最大限度地释放产业价值。
The types of cell biological industry in China show a trend of diversification, and the deepening of cell biological clinical research will further accelerate the formation of the cell biological industry ecosystem with the expansion of ecological cooperation, and the improvement of the ecosystem will promote the rapid development of the industry to a large extent. Data show that the financing amount of Chinese cell therapy enterprises keeps increasing, from 20 million yuan in 2014 to 2.89 billion yuan in 2019. Among them, in 2018, the financing amount of Chinese cell therapy enterprises increased by 706.8% year on year, showing a rapid development trend. In the future, the development of China's cell biology industry will be full of opportunities and challenges. The development of subsequent industries will be accelerated with the application of new technologies such as 5G and ARTIFICIAL intelligence. In the face of the changing market pattern, enterprises should also actively carry out ecological cooperation and pay close attention to the trend of market demand, deeply integrate therapy and new-generation medical innovation technology, realize the diversification and differentiation of market products, and launch unique precision therapy, so as to maximize the release of industrial value. -
艾媒报告|2019-2021年中国中药材行业发展现状及产业链分析报告
本报告研究涉及企业/品牌/案例：白云山,同仁堂,云南白药,昆明制药,华润三九,天士力,央视财经,牛黄,薏仁,茯苓,黄芪,川芎,片仔癀,中国中药,紫鑫药业,九洲药业,陇神戎发,众生药业,通化金马,江中药业,寿仙谷,新天药业,盘龙药业,佛慈制药,昆药集团,香雪制药,六味地黄丸,人参养荣丸,四神丸,白蚀丸,血脂康胶囊,茵栀黄口服液,一捻金胶囊,乙肝益气解郁颗粒,二十七味定坤丸,十六味冬青丸,参芪消渴胶囊,十香返生丸,华润三九,红日药业,源和药业,太龙药业,中智药业，培力控股,盛实百草,芍花堂,亳药千草,汇群中药
国内经济增长以及居民消费水平的提高都刺激着中药医疗消费需求的增长。iiMedia Research（艾媒咨询）调查显示，有49%的受访用户倾向中医药治疗，与西药基本持平。2018年中国中药材市场规模达1246亿元，同比增长22.40%，在巨大的需求驱动下，中药材种植面积扩大，药材产量将会持续增长。
中药材主要包括上游种植、养殖市场，中游流通市场和下游销售市场三大环节。目前，中药饮片和中成药生产是中药产业的核心，主要包括中药加工，包括中药配方颗粒、中药饮片加工、中成药制造等。中药饮片领域方面，行业销售收入增速分别在2016和2018年触底回升，华润三九、中国中药、红日药业等上市公司表现良好；中药配方颗粒方面，2006-2016年，中国市场销售额占饮片市场销售额比重由1.2%增加至6.0%，中药配方颗粒或将成为中药饮片加工行业应用广泛的产品；中成药方面，随着国家医改政策的推行，中成药消费需求趋于合理，中成药产量开始回落，但仍处于一个比较高的产量水平，云南白药、白云山、同仁堂、紫鑫药业等上市企业表现良好。
Chinese medicinal materials mainly include upstream planting, breeding market, midstream circulation market and downstream sales market three links. At present, the production of Chinese medicine tablets and traditional Chinese medicine is the core of the Chinese medicine industry, including the processing of Traditional Chinese medicine, including Chinese medicine formula particles, Chinese medicine tablet processing, traditional Chinese medicine manufacturing. In the field of Chinese medicine tablets, the growth rate of sales revenue in the industry rebounded in 2016 and 2018, respectively, china Resources 39, Chinese medicine, Red Day Pharmaceuticals and other listed companies performed well; Chinese medicine formula particles may become a widely used product in the Chinese medicine tablet processing industry, Chinese medicine, with the implementation of the national medical reform policy, the consumption demand of traditional Chinese medicine tends to be reasonable, the production of Traditional Chinese medicine began to fall, but still at a relatively high level of production, Yunnan White Medicine, Baiyunshan, Tongrentang, Zixin Pharmaceutical and other listed enterprises performed well. -
艾媒报告|2020-2021年中国美容美发行业细分领域及总体趋势研究报告
本报告研究涉及企业/品牌/案例：星客多，完美日记，新氧医美；其他提及企业/品牌：海飞丝，阿道夫，沙宣，清扬，潘婷，飘柔，吕，多芬，施华蔻，资生堂，霸王，章光101，欧倍青，卡诗，滋源，丰添，馥绿德雅，索芙特，欧莱雅，花王，美源，爱茉莉，韩金靓，三橡树，利尻昆布，宣若，自然堂，百雀羚，珀莱雅，隆力奇，佰草集，丸美，相宜本草，薇诺娜，毛戈平，雅诗兰黛，兰蔻，SK-II，兰芝，佰草集，高丝，玉兰油、欧莱雅，欧泊莱，旁氏，大宝，郁美净，隆力奇，丁家宜，佳雪，In Style 造型，OnHair Salon，SWANK Salon，My Hair Salon，AUTHOR TNT ATELIER，藤野造型，木北造型，3AM Hair Salon，Amo la Diva 造型，bymiga，OnHair Salon，In Style 造型，藤野造型，P.STYLE 派斯造型，Hair Code 芭曲造型，MG Style Salon，Kraemer Paris 苏豪发廊，TL Hair 造型，3AM Hair Salon，IMPRES 印象美学，In Style 造型，Paya Hair，My Hair Salon，T SPACE 韩式发型，至 ACME STUDIOS，MJ Hair Style，On Star Salon，简发 HAIR 造型，L’Fashion 美发沙龙，AD Hair Salon，DL VOGUE，Cola-Pie 美发沙龙，原宿 Salon，Nice Salon，In Style 造型，OnHair Salon，Mirror Salon，3AM Hair Salon，COO Salon，MIG Salon等
2020年1月21日，全球知名的新经济产业第三方数据挖掘和分析机构iiMedia Research(艾媒咨询) 发布《2020-2021年中国美容美发行业细分领域及总体趋势研究报告》。报告根据艾媒数据中心、艾媒咨询商业情报数据库、艾媒商情舆情数据监测系统基础数据，对中国美容美发行业的发展现状、用户行为和产业链细分领域进行深度分析，并且以新氧等上市公司作为典型案例进行商情分析，深入研究中国美容美发行业运行模式和发展趋势。2019年，中国的美容美发机构约有95%为民营资本，美容美发行业就业人口达2700万人;总体来说，中国美容美发业整体属于小投资、大市场型的服务行业。随着中国美容美发行业竞争愈发激烈，美容美发机构的经营模式正由单一走向综合，形式也日趋多样化，品牌机构趋向连锁加盟、互联网+实体店融合的经营模式发展。
The report conducts an in-depth analysis of the development status, user behavior and industry chain segmentation of China's beauty and hairdressing industry. Listed companies analyze business conditions as a typical case, and study in-depth the operation mode and development trend of China's beauty and hairdressing industry. In 2019, about 95% of China's beauty and hairdressing institutions are private capital, and the beauty and hairdressing industry employs 27 million people. In general, China's beauty and hairdressing industry as a whole is a small investment and large market-oriented service industry. As the competition in the Chinese beauty and hairdressing industry becomes more intense, the business model of the beauty and hairdressing organization is moving from a single to a comprehensive, and the form is becoming more and more diversified. -
- 1
- 2
